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ABSTRACT
A Comparison o f the Functional Efficacy o f Osteoarthritic Knee Joints Following
Viscosupplemeotation Treatment
by
Stephanie Beasley Buford
Dr. Suzanne Pero, Examination Committee Chair
Assistant Professor of Kinesiology
University o f Nevada, Las Vegas

The purpose of this study was to compare two viscosupplementation products,
Hyalgan and Syn\isc, that may be used to treat osteoarthritis (OA) of the knee. Hyalgan
and Synvisc, have both been studied extensively against NSAIDS and placebos and have
both yielded significantly greater improvements in reducing the symptoms associated
with OA. Forty - one patients diagnosed with OA of the knee volunteered to participate
in this study. Each patient received the standard protocol o f lateral injections with
extended knee of 2 ml o f either Hyalgan or Synvisc using a 20 gauge needle. Product
efficacy and functional outcome were assessed using the Western Ontario and McMaster
Universities Osteoarthritis Index (WOMAC) and was administered to every participant
prior to their first injection and again at two and four months post final injection. The
results suggest that both viscosupplementation products are comparably effective in
decreasing pain and stiffiiess, and increasing daily function.
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CHAPTER 1

INTRODUCTION
Osteoarthritis (OA) is the most commonly occurring form of arthritis in diarthrotic
joints, such as the knee. Clinical studies have concluded that OA affects millions of
Americans and is one of the leading causes of disability in the elderly (Clyman & Pompei,
1996; Harris. 1993; Dieppe, Frankel, & Toth, 1993; Simon, 1999). OA is often idiopathic
and results in both mechanical and biological defects that affect all tissues of the joint
cavity. Physiologically, OA is characterized primarily by the degeneration o f hyaline
cartilage, subchondral sclerosis, formation of osteophyles, decreased synovia or increased
synovia with decreased viscosity, and a multitude o f other pathologies (Goorman,
Watanabe, Miller. & Perry, 2000; W right Maurer, & Di Cesare, 2000). Physically, OA is
accompanied by joint pain, tenderness, limited range o f motion (ROM), crepitus, and
minor inflammation (Adams, Atkinson, Lussier, Schultz, Wade, & Zummer, 1995;
Creaamer & Hochberg, 1997). In addition, there is a degradation process in the
articulating surfaces o f the joint associated with OA which appears to be irreversible in a
cycle - like progression.
The cycle is usually initiated by repetitive activity occurring over time which has
resulted in wear and tear or microtrauma to the joint. Synovial fluid is found inside the

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

2
joint space and in the articular (hyaline) cartilage covering the femur and the tibia. In
healthy diarthrotic joints, synovial fluid is viscous with elastic properties. The wear and
tear to the joint associated with OA leads to the dilution of synovial fluid. The dilution of
synovial fluid results in decreased viscosity and elasticity. This decrease results in
increased friction between the tissues located within the joint space which stimulates the
nociceptors (nerves in charge o f transmitting pain to the central nervous system - CNS) of
the joint capsule resulting in the patient's pain and loss of movement and/or function.
Upon restriction o f mechanical movement, there is a decrease in the production of
synovial fluid. The actual movement of synovial fluid within the joint capsule during
actirity initiates the production o f additional fluid. With decreased movement associated
with pain, there is a decrease in fluid production resulting in the dilution o f the synovial
fluid. This is the beginning of the cycle o f OA progression (Uebelhart & Williams, 1999).
A number of byproducts associated with the inflammatory process may also influence the
production o f synovial fluid. Inflammation produces certain chemicals that retard the
stimulation o f synovial fluid production which decreases the ability o f the fluid to saturate
the joint capsule.
Hyaluronic acid (HA), a type o f polysaccharide found in synovial fluid, has recently
become the focus o f treatment for OA. Synovial fluid has many functions in the knee such
as lubrication, shock absorption, nutrition, cell “traffic controlling", and protection for
nerve endings such as the nociceptors. (Peyron, 1993). The two most prominent functions
o f synovial fluid associated with patient comfort include lubrication and shock absorption.
The efficacy o f lubrication and shock absorption is a direct result o f the viscoelasticity of
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synovial fluid. The viscoelasticity of synovial fluid is dependent on its HA content. HA is
found to be deficient in the synovial fluid and in surrounding tissues o f OA affected joints.
This deficiency, again, initiates the cycle. With less movement there is a decreased
stimulation of HA production. The patients’ chief complaint is primarily pain which is
often described as debilitating, resulting in a decrease or cessation of activity. This
decrease or curtailment in activity significantly and directly contributes to the decrease in
viscosity and production of synovial fluid.
The most common treatments o f osteoarthritis include: physical therapy,
corticosteroidal injections, saline lavage, total knee replacement, glucosamine, analgesics,
and nonsteroidal anti-inflammatories (NSAIDS). There are complications and limitations
with each of these options (Creamer & Hochberg, 1997; Dieppe et al., 1993; Harris, 1993;
Wen, 2000; Goorman et al., 2000; Wright et al..2000; Uebelhart & Williams. 1999).
Physical therapy can be costly for the patient due to minimal authorization by insurance
companies. Corticosteroidal injections may only be administered on a intermittent basis
and may be associated with cartilage destruction and synovitis. Saline lavage has rarely
been used due to the documentation that it is only minimally effective. Total knee
replacement is not normally an option except in extreme and desperate cases considering
the magnitude o f the surgery involved, the average age of the patients, lengthy
rehabilitation, and insurance limitations. Glucosamine is a dietary supplement that has not
been FDA approved or widely researched. The two most popular choices for
osteoarthritic treatment are oral analgesics and non steroidal anti-inflammatory drugs
(NSAIDs), with the latter being the most common. Some o f the concerns that have arisen
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with the utilization o f NSAIDs include the fact that OA generally has a low inflammatory
component and that the cost for these drugs averages approximately $55 per month. In
addition, NSAIDs have documented toxic characteristics that may result in gastrointestinal
problems such as ulcers and bleeding (Wu, Shih, Hsu, & Chen, 1997; Creamer &
Hochberg, 1997; Adams, 1993; Adams, Atkinson, Andre, Lussier, Siminovitch, Wade, &
Zummer, 1998; Simon, 1999).
As a result o f these problems, physicians and researchers began investigating other
more efficient and practical forms of treatment. In the early 1960's, a concept termed
viscosupplementation was developed. The theory behind viscosupplementation was to
replace the missing hyaluronan (HA) by injecting a hyaluronan-like substance directly into
the affected joint. When this concept first surfaced, it was used only in European
countries in joints of horses and then a few years later it was used for human eye surgery.
In 1987, Europeans initiated viscosupplentation use for human joints and in 1997 the FDA
approved its use in the U.S. but only in knee joints. Two products are now being widely
utilized as well as researched extensively. These products, Hyalgan and Synvisc, are very
different in molecular weight, viscosity, and administration protocol. However, both
products are made from a hyaluronan base and are injected directly into the affected joint
capsule. The ultimate goal for each product is the same, to decrease the pain and stiffiiess
in arthritic joints resulting in increased activity levels for patients. Both products have
been clinically proven to accomplish this task more effectively and efficiently than the
alternative forms o f treatment. Most studies support the efficacy o f Hyalgan and Synvisc
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when compared to other treatments and to placebos. Currently, however, there are no
published studies that compare the efficacy o f Hyalgan and Synvisc to each other.
Furthermore, the results from previous studies have revealed that each product
demonstrates a potential downfall which may detract patients from choosing
viscosupplementation as a treatment choice, especially when only one treatment product
option was given. There have been some reports of Injection site pain and swelling
associated with the use o f Synvisc which has a significantly higher molecular weight than
Hyalgan (4 to 6 million daltons vs. 500.000 to 700,000 daltons respectively). The pain
resulting from the injections may contribute to patients not returning for subsequent
injections to complete the treatment protocol. Due to Hyalgan's lower molecular weight,
the administration protocol consists of five intrarticular injections over a five week period
as compared to Synvisc's three injections during a three week period. The fact that five
injections are required for the Hyalgan protocol may deter some patients from exploring it
as a treatment option.
The purpose of this study is to compare the functional efficacy o f Synvisc to Hyalgan
to determine if either viscosupplementation product is more effective at decreasing pain
and stiffiiess and improving the functional activity levels o f patients suffering from OA of
the knee. While it is widely accepted that both Hyalgan and Synvisc are effective in
alleviating the symptoms o f OA, it is crucial to note that viscosupplements are attempting
to treat the underlying cause o f OA and not just the symptoms as is the case with the other
available osteoarthritis treatment protocols. However, due to the reports o f adverse
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affects associated with the different products, the information obtained in this study may
be crucial in determining the most effective course o f treatment for each patient.
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CHAPTER 2

LITERATURE REVIEW

Brief .Anatomy and Physiology o f the Knee Joint
The tibiofemoral joint (knee joint) is the largest and one o f the most complex joints
in the body (Pfeiffer & Mangus, 1995; Magee, 1987). The knee is considered a modified
hinge joint or a trochoginglymus joint because not only can it perform extension and
flexion movements but rotational movements as well (Thompson & Floyd, 1994). There
are several components responsible for the complexity of the knee joint. The femur and
the tibia articulate to form the major portion of the joint. These bones are held together
and stabilized by several ligaments, primarily the cruciate and collateral ligaments. The
space between the tibia and the femur is filled by two meniscL often referred to as articular
discs, that provide lubrication, nourishment, and cushioning for the joint. The patella
(knee cap) is a sesamoid bone that is completely encapsulated by the quadriceps tendon
and articulates with the femur but not with the tibia (Pfeiffer & Mangus, 1995). Bursae
and fat pads are also found within the knee joint and serve to cushion and protect the
articulating surfaces during movement and weight bearing activities. The synovium is a
lining that lies beneath the patella between the tibia and femur creating a sac which
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encapsulates all the components o f the knee joint except for the cruciate ligaments
(Thompson & Floyd, 1994; Hertling & Kessler, 1996). The synovial sac contains synovial
fluid which is extremely important for the health o f the joint components due to its
viscoelastic components. This viscoelastic characteristic o f synovial fluid is highly
dependent upon the content o f a certain polysaccharide called hyaluronic acid (HA)
(Mensitieri, Ambrosio, laimace, Nicholais, & Perbellini, 1995). In normal, healthy joints
the viscosity of the synovial fluid provides lubrication, shock absorption and nutrition to
the articular cartilage and joint surfaces. Without the viscous synovial fluid, the joint
surfaces begin to wear creating joint inflammations, injury, trauma, pain, and disturbing
proper joint function (Wu, Shih, Hsu, & Chen. 1997). In the normal knee, there is
approximately 2.5-3.5 mg/ml o f hylauronan with a molecular weight o f 4-5 million
daltons. In the osteoarthritic knee, there is approximately .8-2 mg/ml of hyaluronan with a
molecular weight of about 4 to 5 million daltons.

Osteoarthritis
Osteoarthritic diseases are a result o f mechanical, biological, biochemical, and
enzymatical processes (Creamer & Hochberg, 1997; Harris, 1993; Clyman & Pompei,
1996). Osteoarthritis (OA) is physiologically characterized by deterioration and loss of
articular cartilage, subchondral sclerosis, osteophyte formation, inflammation of the
synovium and deterioration o f the supporting structures o f the joint. (Adams, 1993;
Goorman, Wantanabe, Miller, & Perry, 2000; Wright, Maurer, & Di Cesare. 2000). OA is
the most common form o f articular cartilage degeneration. Its prevalence generally
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increases with age and physical activity (Wu, Shih, Hsu, & Chen, 1997). Cartilage
damage in OA is likely due to the release o f enzymes from the chondrocytes into the
matrix which lead to additional cartilage matrix degradation. With cartilage damage,
fragments o f collagen, proteoglycan and other matrix components are released into the
cartilage and synovial fluid (Simon, 1999). These may initiate or accelerate an
inflammation reaction in the synovial membrane by acting as neoantigens or irritants. The
inflammation in the membrane creates a cycle with additional cartilage being degraded and
those degradation products provoking increased inflammation (Pelletier & Pelletier,
1993). Inflammation of the synovial membrane is often seen in a clinical setting as a
painful, swollen and hot joint. Whether OA is related to physiological problems or normal
mechanical wear and tear, the joint pain can cause limitations in a patient’s enjoyment o f
life. Patients experience pain with motion, gelling phenomenon, and crepitus. The most
prominent symptom of OA is pain which is usually aching in nature and often poorly
localized. In the early stages, the pain usually occurs in an active joint. However, there
are many complaints of moming stiffness which is short-lived lasting between 15 and 30
minutes. Management of OA entails the use o f drugs, physical measures and/or surgery.
The goal of treatment is to treat the symptoms by relieving pain allowing the patient to be
as active and independent as possible. Because OA has a mild component of synovial
inflammation, the most commonly used medication for treatment are NSAIDs. Chronic
NSAID therapy is associated with an increased risk o f renal side effects, G1 side effects
including ulceration and bleeding, and negative effects concerning bone metabolism (Wu
et al., 1997; Creamer & Hochberg, 1997; Adams, 1993; Adams, Atkinson, Andre, Lussier,
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Schultz, Siminovitch, Wade & Zummer, 1995). Other analgesic agents that are used and
do not carry the GI or renal side effects are acetaminophen (600 mg bid) and
propoxyphene (100 mg qid) but these medications are usually only minimally effective.
Corticosteroids are also used but should not be injected more than four times per year
because there is some evidence o f accelerated cartilage loss and bone atrophy.
Cryotherapy and thermotherapy may also be used to relieve symptoms. Physical therapy
and exercise programs attempt to decrease muscle atrophy and increase or maintain ROM.
Surgical intervention, including total knee replacement, is indicated for patients who have
limited function and intolerable pain (Harris, 1993; Wu et al.. 1997). Osteoarthritis is the
most common form of articular cartilage degeneration. At the present time, no definite,
long term treatment exists for the majority of patients suffering from this disease. OA
effects nearly 16 million Americans and is one of the leading causes of disability in adults
over age 65 (Clyman & Pompei, 1996). Osteoarthritis o f the knee is responsible for a
huge portion o f suffering and disability that results in substantial health care expenditure
(Dieppe, Frankel & Toth, 1993).

Hyaluronic Acid and Synovial Fluid
In human arthritis, the elasticity and viscosity of the synovial fluid are much lower than
in the normal joint (Balazs & Denlinger, 1993; Goorman et al., 2000). Within the matrix
or ground substance that fills the space between cells o f the knee joint is a substance called
hyaluronic acid. Hyaluronic acid (HA) is a long muccopolysaccharide (or
glycosaminoglycan) chain made up by repeating units o f N-acetyl-D-glucosamine and D-
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glucuronic acid (Balaz & Denlinger, 1993; Mensitieri et al., 1995). HA is plentiful in
cartilage and synovial fluid, and is responsible for several actions: a lubricant and a shock
absorber; an energy storing agent between the opposing cartilages; a selective molecular
sieve; a cell traffic controlling agent; a viscoelastic shield around the synoviocytes and the
adjacent nerve endings such as nociceptors. All these actions depend on the high
viscoelasticity o f the HA in normal joint fluid (Peyron. 1993; Adams et al., 1995; Simon,
1999; Goorman et al., 2000). HA is an important constituent of normal human synovial
fluid and is both quantitatively and qualitatively abnormal in osteoarthritic knees. The
performance of human articular joints is strictly connected with the viscoelastic properties
of synovial fluid which determine load transmission, lubrication, wear inhibition and
protections of the articular cartilage and soft tissue surfaces from mechanical stresses
during joint function. The viscoelasticity of synovial fluid mainly depends on the
concentration, molecular weight, and interactions with other molecules (Uebelhart &
Williams, 1999). It has been reported that due to abnormal reactions in the synovial fluid,
the HA concentration decreases in the course o f OA. As a consequence of these reactions
and modifications, the theological properties of synovial fluid appear to be very different
from those o f normal ones. The reduction o f synovial fluid viscoelasticity allows the
cartilage to cartilage contact which results in an increase in surface wear and damage that
ultimately causes pain, sometimes intolerable (Mensitieri, Ambrosio, lannace & Nicolais,
1995; Listrat, Ayral, Patamello, Bonvarlet, Simonnet, Amor & Dougados, 1997).
Hyaluronan serves as a primary isolating and lubricating agent. Most o f the joint capsule
of the knee is completely saturated within the hyaluronan molecular network. The primary
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role of the hyaluronan molecular network is to surround and protect the surface collagen
structure of the cartilage and synovial membrane. Hyaluronan is present in arthritic fluid
but in a lower molecular weight form resulting in less effectiveness to the joint due to a
decrease in molecular interaction and HA concentration as a result o f dilution from
exudation (Al-Assaf. Meadows, Phillips & Williams, 1996; Listrat et al., 1997)). In OA
patients, the synovial fluid is more abundant and less viscous. The HA molecules are
smaller and fluiher apart which decreases the Theological properties o f the synovial fluid.
The concentration of H.A is decreased and the molecular weight is reduced (Peyron,
1993). Elastoviscosit) of HA is extremely dependent on the shear forces to wtich it is
exposed. .At very low frequency, the solution is very viscous with decreased elastic
properties. At higher frequency the solution is extremely elastic. This means that when
extemal forces move these solutions slowly, they behave like viscous fluids and when
movement is fast they behave like elastic bodies. The movement o f the joint generates
flow of synovial fluid that maintains a continuous exchange between the synovial fluid and
the intercellular fluid of the joint tissues (Balazs & Denlinger, 1993; Pelletier & Pelletier,
1993 ). Diminished viscoelasticity o f the synovial fluid alters the mechanical force
transmission to the cartilage increasing its susceptibility to mechanical damage or wear and
tear. In the normal knee joint, there is approximately 2 ml o f synovial fluid, the molecular
mass o f hyaluronan is about 4 to 5 million daltons and the estimated total hyaluronan is
between 4 to 8 mg.
HA is an extremely important component within the joint because it creates a thicker
fluid consistency. This type o f consistency gives the tissues a greater cushioning and
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stability effect. HA gives the joint a “gel-like" environment. The lower the HA content,
the more watery the encapsulation becomes resulting in a less stable environment with
unnecessary movement and friction among tissues. This friction such as bone rubbing
bone or cartilage is the cause o f the debilitative pain for patients.

Viscosupplementation
Viscosupplementation is direct injection o f a hyaluronan (HA i substance into the joint
capsule of the OA affected joint. H.A for this procedure is extracted from rooster combs,
umbilical cords, or from bacterial cultures (Wright et al., 2000). The HA is separated
from any pro-inflammatory, immunogenic, pyrogenic or chemotaiic constituent, while
preserving its polymerization. Its purpose is to increase the rheological properties o f the
joint not only aiding the joint but consequentially reducing the fAysical problems that
become chief complaints of the patients. The concept of viscosupplementation as a
therapeutic modality for treating arthritic pain was invented in the 1960's by E.A. Balazs
and named by J.L. Denlinger in 1989. The first hyaluronan product was initially used to
treat arthritis in horse joints and for humans as a viscosurgical product accompanying eye
surgery. In 1987, viscosupplementadon presented itself to the market as a treatment
modality in human joints, mainly the knee. Very few studies so far have concentrated on
any other human joints such as the hip or shoulder. Currently, the FDA has only approved
viscosupplementation for use in the knee joint.
Pain and loss o f function are the symptoms which generally lead patients to seek
medical attention for osteoarthritis. At present, no medical or physical therapy has been
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shown convincingly to affect the rate of the deterioration o f the affected joint structures,
so therapeutic efforts are rightly directed to symptomatic relief o f pain and attempts to
preserve joint function. Many types of treatments have a role in the management o f the
pain of OA. These include symptomatic pharmacological treatment with analgesics,
NSAIDS, and intra-articular corticosteroid injections, muscle strengthening exercises,
weight loss, the use o f devices such as canes and orthodics, arthroscopic joint
debridement, joint lavage, total joint replacement, education and counseling (Simon.
1999). While analgesics may be as effective as NSAIDs in treating some patients with OA
o f the knee. NSAIDs are considered a standard treatment for OA. Unfortimately, many
patients either caimot tolerate NSAIDs or suffer serious side effects.
Viscosupplementation has been shown, mainly in European studies, to be a safe and
efficient treatment of OA in the knee with very few side effects. (Adams et al.. 1995).
Several injections are needed (from three to five depending on product) to achieve efficacy
because the rheological properties are so inadequate in the affected knee that it takes a
sufficient amount o f product to restore the elasticity and viscosity o f the synovial fluid in
the joint. Another reason for multiple injections may be the body’s inherent programming
to rid the body of foreign substances, as the body may be eliminating the HA as it is
injected. The importance o f the molecular weight of the product may be crucial in this
capacity. The results o f viscosupplementation therapy might therefore be expected to
depend upon the preparation o f the HA product. Because o f this limitation, hylans
(chemically cross-linked hyaluronans) were developed to improve the efficacy of
viscosupplementation. The purpose o f hylan productions was to substantially increase the
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rheological properties of the injected product beyond those of the defective synovial fluid
and even above those of normal fluid (to compensate to dilution) and to increase the time
of residence o f the injected HA in the joint (Peyron, 1993). Cross-linking hyaluronan
improves its utility for viscosupplementation in several ways. First, the rheological
properties are increased; second, it has a longer retention time in the synovial space; and
third, because o f the cross-links, it becomes more resistant to free radical degradation
(Balazs & Denlinger. 1993; Lussier et al., 1996). However, there has been some
speculation that when using cross linking, the product becomes more "gel-like”. This gel
like substance requires a larger needle for injection and there may be less fluidity in the
joint which may enhance some injection site pain and other side effects that will be
described later. Recommended procedures entail repeated injections which have been
found to be necessary by all investigators to achieve a significant and lasting improvement
regardless of the product preparation. Three weekly injections are a minimum. Results in
practically every published study to date has stated that there is an increase in activity,
functional ability and ROM and also a decrease in pain and stiffness with no major side
effects that may last up to six months with no further injections. Studies report an
increase in the concentration and molecular weight o f HA in the synovial fluid several
weeks after the last injection, pointing to a restoration of HA to near normal. Overall, the
published studies that used a preparation o f HA with a molecular weight o f at least
500,000 - 750,000 daltons, were found to be effective.
Not all viscosupplementation products yield the same molecular weight. In fact, the
two products being used in the United States vary greatly in molecular weight (Hyalgan at
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500,000 daltons - 750,000 dallons and Synvisc at 4 - 5 million dallons). How important is
molecular weight when comparing the efficacy o f these two products? Aviad and Houpt
(1994) addressed this question and found that the common perception was that higher
molecular weight H ,\ was superior to lower molecular weight HA. This theory was based
on the idea that if lower molecular weight preparations o f HA seem to enhance the factors
that help restore the theological properties o f synovial fluid then higher molecular
preparations will enhance this process to an even greater extent. However, they
discovered in the literature that there is not much research to support this claim. Aviad
and Houpt (1994) researched studies by two investigators that rejected the claim o f high
molecular weight HA raising \iscosit>' o f synovial fluid and HA concentration more so
than lower weight HA. Aviad and Houpt researched a study by Hilbert et al., that
compared joints injected with an HA preparation o f 1 - 2 million daltons to a control
group not injected at all. The findings were that the mean concentration did in fact
increase from 1.05 mg/ml to 2.46 mg/ml but only lasted for 2 days. By day four, the
concentration of the treated joints fell to pre-injection levels and there were no differences
in subsequent days between the two groups. In other studies there are similar findings that
high molecular weight HA injections do not cause the synovial membrane to synthesize
high molecular weight HA inside the joint (Aviad & Houpt, 1994).
In addition to the studies comparing the efficacy of molecular weight in HA, a study by
Puttick, Wade, Chalmers, Connell and Rangno (1995) researched the acute local reactions
after viscosupplementation using the crosslinked product hylan GF - 20 (Synvisc). In this
study, the authors used twenty-two patients with a mean age of 63. The recommended
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injection protocol for Synvisc was followed ( 3 injections of 2 ml at weekly intervals). A
total of 88 injections were administered to 28 knees. Ten injections were associated with
reactions such as pain, swelling and warmth, some lasting up to 3 weeks. Four of the
patients had local reactions so severe that there was an increased difficulty in movement.
The synovial fluid of the negatively affected patients was effused and analyzed in an
attempt to determine the underlying cause o f the adverse reaction. The results showed
elevated white cell counts with negative cultures and crystal examinations. The fluid, in
some cases, was yellow and cloudy which was not found prior to injection. This research
resulted in more than one quarter o f the patients experiencing adverse effects to the higher
molecular weight HA. The authors add that the reactions they noted appeared to have
been directly related to hylan (the cross linked product hylan GF-20). Although there
were adverse reactions found, most patients did experience an increase in ROM, a
decrease in pain and stiffness allowing for increased activity level, and a decreased amount
o f unpleasant side effects compared to other forms o f treatment.
After researching three reported cases o f calcium pyrophosphate dihydrate (CPPD)
crystals found in knee joints immediately following treatment o f OA with Synvisc,
Kioesen, Schmid, and Theiler (2000) report a fourth case. This case report describes a 60
year old man who was diagnosed with OA in both knees. There was no history o f crystal
arthropathy, no documented signs o f cartilage calcification, and no family history of CPPD
arthritis. Kroesen et al. (2000) also document that the patient had no form o f CPPD
associated diseases such as haemochromatosis, hyperparathyroidism, hypophosphatasia,
hypocalcaemia, hypomagnesaemia or hypothyrosis. Treatment protocol for Synvisc is one
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injection every week for three weeks. The patient tolerated the first injection very well but
then two days following the second injection a week later, the man developed very painful
swelling, redness and the loss o f function o f his right knee. The results o f many tests
revealed no other indications other than the presence o f rhomboid crystals that were
defined as CPPD crystals. The patient was treated with NSAIDS and a steroid injection
and within a few days, the symptoms totally disappeared. Viscosupplementation treatment
was not resumed.
In studies researching the efficacy o f sodium hyaluronate (for example Hyalgan). a
category concerning the prevalence of adverse reactions due to injection was not included
as a primary focus of the research but was mentioned. European studies reveal that most
o f the events are related to local symptoms such as pain, swelling, heat and redness. The
information following was extracted from a multi-center clinical trial investigation
performed in the United States. The injection protocol followed the recommended five
time, 2 ml solution injections one week apart. This study contained three levels; Hyalgan
treated patients (N = 164); Placebo - conuol - patients (N = 168); and Naproxen treated
patients (N= 163). The mean age across the levels was 64 years with 60% females and
40% males. The adverse events were recorded as: gastrointestinal complaints, injection
site pain, headache, local skin reactions (rash, discoloration), local joint pain and swelling
and local pruritus (itching). The results were statistically significant in the occurrence of
pain at the injection site in the Hylagan patients (23% compared to 13%, p = .022); no
statistical significance between the Hyalgan treated group and the control groups
concerning gastrointestinal complaints (29% vs 36%), headaches (18% vs 17%), local skin

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

19
irritations (14% vs 10%), local joint pain and swelling ( 13% vs l} ’ b) or pruritus (7% vs
4%). The naproxen treated patients were not mentioned in the results unless they were
incorporated into the control group percentages but there was no indication (Sanofi
Pharmaceuticals, Inc., 1998).
Simon (1999) found in published literature that several clinicai trials testing Synvisc
treatment, resulted in patients who dropped out o f the study due tc intense injection site
pain. Simon ( 1999) also noted that subjects treated with Hyalgan left research trials due
to injection site pain and in two cases, anaphylaxis was reported f:Ilowing injection.
Wright et al. (2000) documented researching the same adverse ececis as aforementioned
researchers and also noted cases of erythema, muscular cramps, and hemorrhoids linked to
viscosupplementation treatment.
Viscosupplementation is a modality that attempts to treat the underlying cause of OA
by replacing the HA that affected knees have lost. This means th a the watery and
unstable joint spaces that plague OA patients, can be restored to cushioned, stable and
more “gel-like” environments. Viscosupplementation involves inecting HA directly into
the knee joint. Due to the fact that products such as Hyalgan and Synvisc contain forms
of hylans, the injected substance is thick and viscous. This "thickness” or higher viscosity
may then cause some side effects such as injection site pain and aching. Since both
products are actually foreign to the body at initial injection, the k d y may treat it as such
and try to rid it from the body. This could result in adverse reactions such as swelling,
pain and heat around the injection site or even within the entire joint. Again, because
viscosupplementation is a foreign chemical, certain individuals may react to it in many
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different ways creating may different side effects. This, however, happens with all forms
of medication. Viscosupplementation has been proven by several studies to be more
effective with decreasing joint pain and stiffness and increasing physical functioning than
any other treatment for OA. Furthermore, viscosupplementation has also been proven to
create significantly less side effects than other popular forms of treatment such as
NSAIDS and steroid injections.

Hyalgan
Hyalgan is a viscosupplementation modality that is manufactured by Fidia S.p.A.
located in Abano Terme. Italy. Hyalgan contains per 2 ml syringe: 20 mg o f sodium
hyaluronate (extracted from rooster combs); 17 mg of sodium chloride; 0.1 mg of
monobasic sodium phosphate 2Ho; dibasic sodium phosphate 12Ho; and up to 2 ml of
water. The molecular weight ranges from 500,000 daltons to 750.000 daltons. The
recommended administration of Hyalgan is by intra-articular injection, using a 20 gauge
needle, 2 ml per injection, once per week for five weeks.
Corrado, Peluso, Gigliotti, De Durante, Palmieri, Savoia, Oriani and Tajana(1995)
note that it is widely reported in the literature that intra-articular injections o f hyaluronic
acid (HA) has beneficial effects in osteoarthritis patients physiologically inside the joint
capsule as well as mechanically and symptomatically. Administration of HA can control
the secondary inflammatory process and can stimulate the endogenous synthesis o f HA
intra-articularly. Due to the documented findings, the authors listed above were interested
in assessing whether viscosupplementation of HA could, besides controlling pain, induce a
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significant change in the WBC (leukocyte) pattern o f the synovial fluid in OA patients.
They also decided to measure the quantities of proteins that have previously been
documented at high concentrations in plasma and synovial fluid. The goal o f this research
was to assess 2 characteristics: 1). the components of the cell populations present in
synovial fluid; and 2). the concentrations of albumin and protein present in synovial fluid.
Corrado et al., used 40 patients, 9 males and 31 females with a mean age o f 61 years. The
diagnosis was mono or bilateral OA of the knee with at least 6 months duration of
symptoms. All participants presented at least 3 ml o f joint effusions and pain upon
movement. The patients were randomly divided into two groups, group A (treated with
Hyalgan - sodium hyaluronate) and group B, control group (treated with a placebo).
Administration o f injections were identical in both groups and consistent with the
recommendations already mentioned. Patients were assessed before each injection ( days
0, 7,14.21 and 28). The main criterion was pain on movement measured by the Visual
Analogue Scale (VAS). Secondary criteria was pain at rest also using the VAS, joint
mobility on flexion, a five point scale (0 = none, 1 = poor, 2 = fair, 3 = good. 4 =
excellent) subjective to physician and patient rating treatment efficacy and the volume of
joint effusion aspirated. On day 0 and day 35 tests were completed with blood and
synovial fluid analyzing the phenotype characterizations o f the WBCs and a quantitative
assessment o f proteins. Statistical analysis was performed using the ANOVA test for the
clinical trials and the Wilcoxen’s test for the invasive variables. The results were
(percentages compared to baseline levels which were similar in both groups and following
results were recorded at day 35): pain on movement, group A revealed a 50% decrease in
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pain and group B a 29% decrease in pain; pain at rest, group A = 78% decrease in pain
and group B = 11% decrease in pain; flexion, group A = an increase o f flexion by 9.5%
and group B showed a decrease in flexion by 4%; for joint effusion there was no
statistical significance in either group; physician and patient efficacy rating, positive
judgements (good and excellent) were expressed by physician and patient for group A
68% and group B 25%. The results of the in vivo biochemical measurements o f the
synovial fluid and plasma found reduced levels o f WBCs and a general decrease in the
various protein species studied. Most of these results were statistically significant ranging
from p = .0006 to p=.0482 and the non statistically significant results ranging from p=.06
to 0.7. The results of this study show definite clinical efficacy of sodium hyaluronate in
the knee joint. The results also progress toward biochemical efficacy as well. To improve
the significance of the biochemical results, the same tests could be utilized comparing an
additional level o f normal knee joints (Corrado et al., 1995).
Altman and Moskowitz (1998) completed an extensive and extremely detail oriented
study that researched the efficacy and safety of sodium hyaluronate (Hyalgan). The study
group consisted o f 333 participants ffom 15 different academic and private practice
centers. The inclusion criteria included men and women with a mean age o f greater or
equal to 40 years, a diagnosis o f OA of the knee and pain for at least one year, severity of
pain (on a 50 foot walk) greater than or equal to 20 mm on a 100 mm visual analog scale
(VAS), pain greater than or equal to 20 mm on at least one pain item o f the WOMAC
subscale, moderate or marked pain on a six point categorical (none, slight, mild, moderate,
marked, severe) scale, a knee radiograph o f a Kellegren-Lawrence grade two or three, no
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prior intra-articular injections o f HA within one year, and finally, no other intra-articular
injections o f any other product for at least three months. The study design was double
blind and compared the efficacy o f Hyalgan to naproxen and a placebo. All patients
received the same treatment protocol no matter which treatment group they were assigned
to. Hyalgan patients received the standard intra-articulation injection for the respective
product and also an oral placebo to simulate naproxen. The naproxen patients received
and intra-articulation of saline solution and the placebo patients received saline solution
injection and an oral placebo cosmetically identical to naproxen. .'Ml patients were blind to
what they were receiving and were even draped while receiving the injection. There were
two researchers, one masked and the other unmasked. The blinded researcher performed
and recorded efficacy assessments and was not present for injections or privileged to any
study data. The non-blinded researcher recorded adverse events, monitored laboratory
reports, assured patient blindness, and performed the injections. Participants were allowed
to take 500 mg acetaminophen tablets up to 4000 mg/day as needed for knee pain and
were monitored with subject recorded intake and laboratory results. Treatment efficacy
was assessed by pain during a 50 foot walk, measurement o f knee pain during previous 48
hours by a six point scale, time in seconds to complete a 50 foot walk, WOMAC index by
VAS, heel to buttocks distance in cm, knee range o f motion measured in degrees by
goniometer, midpatellar knee circumference in mm, clinical estimate of synovial effusion
o f the knee, acetaminophen count, and overall evaluation o f treatment effectiveness by the
patient and masked observer. For efficacy, Hyalgan resulted in a significant improvement
with all assessments compared to the naproxen and placebo groups. The naproxen group
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exhibited a lower subject usage o f acetaminophen than the Hyalgan or placebo group. For
safety, there were significantly more gastrointestinal adverse events associated with
naproxen than with Hyalgan or placebo subjects. Complaints of injection site pain were
significantly higher in the Hyalgan group. Ecchymosis, rash, headaches, and pruritus
revealed no statistical difference among any group and were noted in all. There were four
reports of severe knee swelling and/or effusion, one in each naproxen and placebo group
and two in the Hyalgan group. The efficacy and safetv measurements of this study
ultimately support that Hyalgan when compared to naproxen or a placebo is the preferred
method of treatment for OA of the knee with significant pain reduction, functional
improvement and no major adverse effects when compared with the other two study
groups (Altman & Moskowitz. 1998).
There is another type of viscosupplementation product which is also characterized by
a molecular weight ranging between 500,00 daltons and 750.000 daltons and containing
mostly sodium hyaluronate. This product, ARTZ (Seikagaku Co.), is currently being used
in the Asian countries but not in the U.S. Wu, Shih. Hsu, and Chen (1997), also
compared sodium hyaluronate (ARTZ) with a placebo. Participants consisted o f 90
patients with 116 knees diagnosed as mild to moderate osteoarthritis. The diagnostic
criteria included symptoms with exercise pain, decreased ROM, radiologic findings of
bone spurs, joint space narrowing or osteosclerosis. The research design was double
blinded using two groups. The test drug was 2.5 ml of a sodium hyaluronate solution and
the placebo was 2.5 ml of a solvent for ARTZ. The injection protocol for both groups
used the five injection administration once a week for five weeks. No local anesthetics.
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NSAIDs or physical therapy were allowed. Evaluation items were clinical symptoms and
were as follows: resting pain, walking pain, up/down stairs pain, flexion/extension pain,
oppressive pain, swelling, estimated amounts o f synovial effusion, and ROM o f joints.
The parameters were subjective and divided into four categories: no symptoms, mild,
moderate or severe symptoms. The sv-novial fluid was measured in milliliters (ml). Other
evaluations included general improvement and was judged by evaluating clinical symptoms
and daily activities comparing before and after treatment values. These values were
ranked in seven categories: 7 excellent improvement. 6 improved. 5 fair improvement, 4
unchanged. 3 slightly worsened. 2 worsened, and 1 markedly worse. All parameters were
recorded at zero weeks and five weeks, before each injection and one week after total
injections. Statistical analysis was calculated using the ANOV.A. Student's t-test, Mann*
Whiteney U test and Chi-Square. Results indicate that there was a statistically significant
improvement in all areas of the ARTZ treated group compared to the placebo group and
both compared to baseline measurements. The most prominent improvement was the
efficacy of ARTZ for relief of motion pain and increased ROM. Also, the largest margin
of difference and most improvement across the board was found between five weeks and
13 weeks. After 13 weeks, the margin narrowed and the treatment effects decreased.
This results in marked efficacy between three and six months. During this research, there
were no patient complaints of side effects and no adverse events recorded.
Wobig, Bach, Beks, Dickhut, Runzfaeimer, Schwieger, Vetter and Balazs (1999)
published a study that compared hylan GF-20 (Synvisc - 6 million daltons) to a lower
molecular weight hyaluronan (ARTZ - 0.75 million daltons). The purpose of their study
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was to compare the viscoelastic properties of Synvisc and ARTZ to determine a
relationship of elastoviscosity to positive treatment outcome in patients with osteoarthritis
of the knee. The study was a 12 week, double blinded, randomized, multi-center study
with a total of 70 patients (38 received Synvisc and 32 received ARTZ). The patient
inclusion criteria required a radiographically confirmed diagnosis of primary idiopathic OA
of the knee, a certain amount o f erythrocyte sedimentation, and knee pain that was
unaffected by other treatments. Treatment initiation followed a two week washout period
and was exactly the same for each product. The participants were randomly separated
into the two groups, either Synvisc or ARTZ. and w ere given 2 ml injections of the
respective solutions to knees with no effusion using 18 to 20 gauge needles. In both
groups, there were three injections given at one week intervals between each injection.
Efficacy detemiination was based on results from the WOMAC index and adverse reaction
results were based on patient interviews. The statistical analysis resulted in Synvisc having
a significantly greater pain relieving effect than ARTZ with no significantly greater
incidence of adverse effects.
Mensitieri, Ambrosio, lannace and Nicolais (1995) compared the efficacy o f two knee
osteoarthritis therapies: viscosupplementation with sodium hyaluronate and arthrocentesis
(aspiration of knee effusion). This study deals with the theological evaluation o f synovial
fluid. Fluids were extracted before and after viscosupplementation, arthrocentesis and
placebo therapies to obtain and measure entities that could explain the efficacies o f each.
The synovial fluid was extracted from 60 patients vvho had clinical and radiological signs
of OA for at least six months. The participants were randomly assigned to three different
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groups: the exogenous HA group, the placebo group and the arthrocentesis group. The
HA group was injected with Hyalgan according to the recommended five injection, one
week margin, guidelines. The placebo group was also injected according to the same
guidelines as the HA group but with 2 ml of placebo. The theological properties of the
extracted synovial fluid was measured using a Bohlin VOR Rheometer. The viscoelastic
evaluation of the efficacy of the different therapies was based on the analysis o f synovial
fluid frequency sweeps which indicated that the fluid in all groups before treatment was
diluted resulting in a reduction of theological properties. The same measurement was
utilized in the synovial fluid extracted after the treatment and this is what Mensitieri et al.
found. The arthrocentesis yielded synovial fluid with a decrease in HA concentration and
molecular weight and an increase in concentration o f proteins. There is no endogenous
stimulation of HA in the joint capsule following arthrocentesis. The Hyalgan treated
group showed an increase in H.A concentration and molecular weight. The authors of this
study state that the hypothesis that exogenous HA enhances the in vitro production of HA
can be confirmed by this theological analysis (Mensitieri et al., 1995). The conclusion is
that even though viscosupplemented HA has been proven by other research to be short
lived in the joint capsule, that short time can stimulate the production of endogenous HA.
This is an important finding considering that OA is a degenerative disease that has
received only treatment for the symptoms. Perhaps the longer a patient receives HA
injections, the more endogenous HA can be stimulated from its own tissues.
The focus of a study completed by Kotz and Kolarz (1999) consisted o f three
objectives for patients treated with Hyalgan. The first objective was to research time
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intervals from the first sign of improvement following the initial injection. The second
objective was the duration of improvement after the treatment cycle (all 5 injections) and
lastly following a second treatment cycle if a renewed need for therapy occurred the fourth
month and twelve month after the fifth injection from the first cycle. Subjects consisted of
77 women with a mean age of 59.5 years and 31 men with a mean age o f 53.0 years.
Participant criteria included sole diagnosis of OA of the knee, subjective complaints for
one year, knee pain for at least 20 days of the month, and a value o f greater than or equal
to 3.3 on a 10 cm visual analog scale (VAS) with 0= no pain and 10=maximum pain
concerning numerous activities. The last criteria would serve as baseline measures and
would be taken before beginning any treatment. Examinations were performed at day 0.
7.14. 21, 28. and 35 during the treatment cycle and then monthly thereafter. Treatment
safety was assessed by monitoring several various laboratory tests and by recording any
adverse effects that may have occurred between each exam. If there was a need for any
subject to begin another cycle of treatment the first injection o f the second cycle could
begin anywhere between the end of the fourth month and the beginning of the twelfth
month. Patients engaging in a second cycle were monitored the same as the first cycle.
This study resulted in three years of research from 1991 to 1994. Statistical analysis was
performedby using Student’s t test, with the alpha level set at p<0.05. The study resulted
in an improvement in 95% of the subjects with descriptions ranging from symptom free to
slight improvement. There were 119 instances of adverse effects recorded ranging from
back pain, injection site reaction, injection site pain, and joint effusion (Kotz & Kolarz,
1999).
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Many other studies have been completed focusing directly on Hyalgan but the research
was performed “in-house”and is unavailable in published literature. The following
information was supplied directly from the company which markets Hyalgan. A double
blind, three level (Hyalgan, naproxen, and control), 26 week study used 495 patients
ranging in age between 40 and 90 years to test the efficacy of Hyalgan (sodium
hyaluronate). Clinical assessments included the Visual Analog Scale (VAS) and the
Western Ontario and McMaster University Osteoarthritic Index (WOMAC). Hyalgan
patients received the recommended administration of Hyalgan as mentioned earlier and a
naproxen placebo. Naproxen patients received 500 mg b.i.d.(twice per day) and no
injections and the control patients received a naproxen placebo plus saline injections
following the same protocol as the Hyalgan group. .All patients received subcutaneous
lidocaine and were allowed to take no more than 4 g/day of acetaminophen. The results
showed that the Hyalgan patients achieved a statistical significance in the VAS 50 foot
walk category and maintained the improvement for over six months (p=.03 compared to
the control group and comparable to naproxen). In the patient’s categorical assessment of
pain the percentages o f slight or no pain were as follows: Hyalgan 47.6%; Naproxen
38.9%; and control 33.1%. Injection site pain was the only adverse event occurring more
in the Hyalgan group (23%) than the control group (13%). Other adverse events such as
headaches, GI irritation, itching, etc. were not significant to any group.
Research studies have found that Hyalgan significantly decreases pain and stiffiiess and
increases range o f motion and daily fimctioning. Studies have also concluded that the use
of Hyalgan through viscosupplementation may actually stimulate the body to begin
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manufacturing small amounts o f endogenous HA. Although there were a number of
adverse events linked to the utilization o f Hyalgan, the research strongly suggests that
there are still less side effects resulting from Hyalgan injections than other forms of
treatment (NSAIDS, etc.) and more importantly, Hyalgan’s treatment was much more
effective than those other forms o f treatment.

Synvisc
Synvisc is a viscosupplementation modality that is manufactured by Biomatrix located
in Ridgefield, New Jersey. Synvisc contains per 2 ml syringe: 16 mg Hylan A and B: 17
mg sodium chloride; .32 mg disodium hydrogen phosphate; .08mg sodium dihydrogen
phosphate monohydrate, and water. The molecular weight ranges from 4 million daltons
to 6 million daltons. Recommended injection of Synvisc is intra-articular injection. 2 ml
syringe with an 18 gauge needle, once a week for three weeks.
Adams, Atkinson, Lussier, Schulz, Siminovitch. Wade and Zummer (1995) conducted
a study to determine the safety and efficacy of viscosupplementation with hylan GF-20
(Synvisc) used either alone or along with continuous NSAID therapy. The purpose was
to evaluate whether hylan GF-20 can prevent a fiare in pain when NSAID therapy is
discontinued. The 93 patients were men or women between the ages of 18 and 75 years
with a diagnosis of idiopathic OA o f the knee. Patients had to satisfy some of the
following criteria: I) morning stiffiiess not longer than 30 minutes; 2) crepitus on active
motion; 3) tenderness o f the bony margins; and 4) physician determination o f absence of
rheumatoid disease. All the participants also needed to have been taking NSAID therapy
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for at least 30 days prior to trial without significant side effects, to have been actively
using the affected joint on a daily basis and a VAS score of >50 nun out o f 100 nun for
pain on motion with weight bearing. Patients were then randomly assigned to one of three
treatment groups. The NSAID only treatment group received a series of three weekly
arthrocenteses and continued to take the NSAIDs as before and throughout the trial. The
Hylan GF-20 only group discontinued the NSAID dosage and instead only received
viscosupplementation according to the recommended guidelines, 2.0 ml per week for three
weeks. The third group continued the before trial NSAID dosage in addition to receiving
injections o f hylan GF-20 following the group two protocol. No placebo group was
included. No other treatment was allowed except acetaminophen which was only to be
taken upon emergency basis. If acetaminophen was ingested, the participant was to
document reasons and dosage in a daily diary and was instructed to notify the
investigators. Patients were evaluated before injections began for baseline values. The
subsequent evaluations were at each injection three weeks apart, at week 7 and week 12.
The patients were also evaluated through a phone interview at week 26. Efficacy
variables were measured at each meeting using a 100 mm VAS. The variables were; pain
on motion with weight bearing; pain at rest; pain at night; restriction of activity; patient’s
overall assessment o f arthritic pain; pain during a 50 foot walk; medial joint tenderness;
and evaluator's overall assessment of tbie treatment. Efficacy variables were measured on
an ordinal scale correlating numbers with signs and/or symptoms. Adverse events were
also reported and recorded at each visit Categorical analyses were performed for each
outcome measure defining improvement at a VAS score of below 20 mm. ANOVA was
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used for analysis of continuous data and comparisons among the three groups. Fisher’s
LSD multiple comparisons test was used to distinguish between individual treatments.
Paired t-tests were used to evaluate efficacy by comparing pre and post treatment values.
The chi-squared test and tests of proportions were used to analyze categorical data. For
the severity of pain variable which did not follow continuous distribution, an ANOVA of
ranked data was used. Least square means were calculated from the individual
improvements and used for comparisons among all three groups (Adams et al.. 1995).
The only statistically significant results up to the 12 week evaluation among the groups
were found for pain at night and support used. Although both groups of hylan injected
patients showed better results than the NSAID alone treated group, the results were not
statistically different. This explains that hylan GF-20 is at least as effective as NS.AlDs up
to 12 weeks. At the 26 week phone interview, the data obtained did demonstrate some
statistically significant differences. Data was received from the patient by only using the
patient-evaluated VAS variables as in all the previous evaluations. The investigator was
only able to judge the patient's perception o f the clinical condition rather than actually
performing it. The hylan groups both showed significantly less pain at this time then the
NSAID only group. This could mean that there are benefits occurring up to six months
following one course of hylan injection. Adverse events were reported and recorded.
Only 6 patients of the 93 were documented as having some type of adverse event during
the trial. Three of those participants were excused from this category because the events
were not related to the injection but instead unrelated factors. The three participants who
remained in this category all began to experience the adversity approximately 24 hours
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following injection including warmth effusion and a high WBC count in their synovial
fluid. These side effects were recorded as not severe and were absent with in a week.
Although this study was extensive and lengthy, what needs to be deduced is that the
results show that hylan GF-20 is at least as effective as NSAIDs in the relief o f pain and
increase in activity and maybe even more so, just not supported statistically. There was a
minimal number o f side effects reported and the efficacy seems to be lengthy.
Lussier. Cividino. McFarlane, Olszv nski, Potashner, and Medicis conducted a long
term, case study style investigation of hylan GF-20 on 336 patients (458 knees) from 1992
to 1995. The information collected from each patient included demographics, disease
characteristics, injection technique, and information with respect to hylan treatment historysuch as efficacy and adverse reactions. Participants consisted of 125 males and 211
females with a mean age of 65 years. Patients underwent two courses of
viscosupplementation. Each course consisted o f three. 2 ml injections of hylan GF-20
once a week for three weeks. Clinical efficacy was evaluated by the patient’s opinion of
treatment and any changes in pain or activity level. This was measured on a five factor
ordinal scale (much better, better, same, worse, much worse). Following the first course,
77% of the knees were either better or much better with pain and following the second
course, 87% o f the knees fell under the same two categories. Activity level after the first
course was 76% better to much better and following the second course. 84% were better
to much better. The survey also collected data on any changes in the patients normal use
of pain relief therapy after the viscosupplementation treatment. Over half o f the
participants either decreased or stop using any additional form of therapy such as
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analgesics, NSAIDs or steroidal medication. Radiological data was gathered from these
patients to compare the in vitro response to hylan injections. Grades I, II and III OA were
studied and although there was improvement seen in all cases, only a statistically
significant difference (using chi-square analysis) was noted in the early and intermediate
stage patients compared to the end stage o f OA (p = <.05 ). The duration o f clinical
benefit after hylan injection was analyzed in two ways. The first method was based on the
evaluation of the investigator which led to the opinion that the majority o f patients
demonstrate clinical benefits from three months to 12 months. The second method was
based on the time that elapsed between the first course of treatment and the patient's need
for a second course of treatment. The mean duration was eight months with a range of
two to 18 months. Twenty eight patients reported local adverse events mainly pain,
swelling and heat and on a mild to moderate level. 72% of the reactions were considered
to be possibly or probably due to the hylan injection. These adverse events were transient
in most patients with no further problems. The relationship between the incidence of
adverse events and the injection technique used to administer the hylan were documented.
The categories for injection entry were: medial straight; medial flexed; lateral straight;
lateral flexed; and intrapatellar. The greatest percentage o f adverse events was observed
with a medial flexed approach which was statistically significant to the other categories
(p=.014 - p=.017) (Lussier et al.,). Conclusions of this study are that hylan GF - 20 seems
to be effective in the decrease o f OA symptoms and can last several months with a low
incidence of adverse effects.
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As with Hyalgan. research studies have found that Synvisc is significantly more
effective in decreasing pain and stiffness and increasing range of motion and daily
functioning than other forms of treatment such as NSAIDS, analgesics, saline, etc...
Furthermore, Synvisc is more easily tolerated than other forms of treatment and although
adverse reactions have been noted, they are significantly less than associated with the
utilization o f other forms of treatment.

Hyalgan vs Synvisc
In 1997. the FDA approved the only two products to be used as viscosupplementation
therapeutic devices for osteoarthritis of the knee in the United States. Hyalgan and
Synvisc. The previous documented review of literature provided numerous facts revealing
the differences in these two products in consistency, molecular weighu and incidence of
adverse reactions. In addition to product efficacies, another consideration of high
importance to the patient is economics. As mentioned earlier, NSAIDs have an average
cost of roughly $55 per month. The actual wholesale price (AWP) for Hyalgan is
approximately $635 per course o f therapy (5 injections). Synvisc’s AWP is approximately
$619 per course of therapy (3 injections). Ultimately, the cost for the patient, depending
on insurance, will equal about 20% of a price equal to the AWP or lower. For example,
the price for Hyalgan users will be approximately $120.60 per course of therapy and the
price for Synvisc will be about $117.74 per course o f therapy. Over a 4-6 month course
o f treatment, the cost per month ranges between $20 and $30 per month, a definite
economic value over continued NSAID use. The research also revealed the efficacy of
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both products in treating OA of the knee and the superiorit) o f viscosupplementation
treatment as compared to NSAIDS or placebo treatment groups. To date, there have
been several studies comparing each product to other forms o f OA treatment or efficacy
against some type of control or placebo group but no published information has been
found directly comparing the efficacy or functional outcomes o f each product to the other.
Research supports that, in most cases, viscusupplementation is the most effective
choice in the treatment o f osteoarthritis of the knee as it attempts to treat the underlying
cause o f the disease rather than the associated symptoms. Currently, doctors and patients
in the U.S. have two FDA approved product choices. Hyalgan and Synvisc. Although
Hyalgan and Synvisc have identical overall goals, there are also many significant
differences between the two viscosupplementation products. The two most prominent
differences surround the molecular weight and injection protocol, both o f which have been
linked to the incidence o f adv erse reactions. Based on the differences between these two
products as identified in the literature, this research study will directly compare Hyalgan to
Synvisc in an attempt to determine if there are any overall efficacy or adverse event
differences between the two viscosupplements.
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CHAPTERS

METHODS

Participants
Fort) - one participants (20 Hyalgan, 21 Synvisc) mixed in gender, age. and ethnic
background volunteered through their physician's office to participate in this study.
Twelve men and eight women with a mean age of 64 years comprised the Hyalgan group
and 15 men and six women with a mean age of 62 constituted the Synvisc group. The
physicians were utilizing viscosupplementation prior to becoming study contributors.
Volunteers for this study were patients o f these physicians who already made the decision
to try viscosupplementation as a treatment. A clinical diagnosis of osteoarthritis o f the
knee must have been made by the treating physician prior to the study. Participants were
excluded if they had any previous experience with viscosupplementation treatment,
engaged in any form o f physical rehabilitation or exercise therapy for OA o f the treatment
knee, planned to initiate any prescription analgesic or anti-inflammatory medication after
the first injection, consumed glucosamine supplements, received saline lavage, or
corticosteroidal injections. The patients using over the counter analgesics and anti
inflammatories on a regular basis and at a consistent dosage to treat their OA prior to the
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first injection were allowed to continue using the medication but were not allowed to
increase the dosage or frequency. This study was approved by the University o f Nevada,
Las Vegas Institutional Review Board (Appendix A) and all participants signed informed
consent forms prior to participation(Appendix B). Participants were informed o f their
right to withdraw from the study at any time.

Instrumentation
The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)
(Appendix C) was developed by Dr. Nicholas Bellamy in 1981. The WOMAC is a tri
dimensional. disease specific, self administered, health status measure (Bellamy. Buchanan.
Goldsmith, Campbell, & Stitt, 1988) that is utilized for the detection of clinically
important changes in health status o f osteoarthritis following a variety of interventions
such as: non-steroidal anti-inflammatories (NSAIDS), analgesics, physical therapy,
corticosteroids, joint replacement, arthroplasty, and viscosupplementation (Bellamy &
Buchanan, 1986; Bellamy, Wells, & Campbell, 1991; Bellamy. Buchanan. & Chalmers.
1992). The WOMAC is an index consisting of 24 questions that focus on clinically
important symptoms in patients with osteoarthritis of the hip and/or knee. The questions
include: five pain, two stiffiiess, and 17 physical function (daily activities), and can be
completed in less than five minutes. Bellamy, Buchanan, Goldsmith, Campbell and Stitt
have completed two major studies to assess the validity and reliability of the WOMAC
index. Both studies concurrently administered the WOMAC index along with the
Modified Doyle Index, the Lesquesne Index, the Bradbum Index o f Well-Being, and the
Social Component o f the MHIQ to the participants for validation purposes. Reliability
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was tested with pain, stiffness, and daily function and determined using Cronbach's alpha.
Values for pain were: pre = 0.88, mid = 0.88, and post = 0.93. Values for stiffness were:
pre = 0.87, mid = 0.73, and post = 0.96. Values for daily function were: pre = 0.88, mid =
0.91, and post = 0.94. Test-retest reliability was determined using Kendall’s tau c statistic
and by using a one week retest interval the values were: pain = 0.64, stiffness = 0.61, and
daily function = 0.72. This study utilized the visual analog (VA) scaled version of the
WOMAC which requires the subject to respond on a 10 cm horizontal line with end
markers that represent extremes. The left end marker describes no pain, stiffness or
difficulty in function for the subject and the right end marker describes extreme pain,
stiffness or difficulty in function for the subject. The subjects placed a mark, preferably an
X ”. on the line where it best represents the way they were feeling at that time in relation
to the question.

Viscosupplements
Hyalgan is a viscosupplementation product that is manufactured by Fidia S.p.A. and
distributed in the United States by Sanofi Pharmaceuticals, Inc. A 2 ml syringe of Hyalgan
contains: 20 mg of sodium hyaluronate, 17 mg o f sodium chloride, 0.1 mg o f monobasic
sodium phosphate 2Ho, dibasic sodium phosphate l2Ho, and up to 2 ml of water. The
molecular weight of Hyalgan ranges from 500,000 daltons to 750,000 daltons. The
recommended administration o f this product is through intra-articular injection, using a 20
gauge needle, 2 ml per injection, once per week for five weeks.
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Synvisc is a viscosuppleracntation product manufactured by Biomatrix. Synvisc
contains per 2 ml syringe: 16 mg of Hylan A and B, I7mg sodium chloride, 0.32 mg
disodium hydrogen phosphate. 0.8 mg sodium dihydrogen phosphate monohydrate, and
water. The molecular weight ranges from four million daltons to six million daltons.
Recommended administration of Synvisc is a 2 ml intra-articular injection with an 18
gauge needle, once a week for three weeks.

Procedures
Subjects were patients who were previously identified by their participating physician
as candidates for a viscsupplementation program for the treatment o f osteoarthritis of the
knee. To participate in this study, the subjects read an information packet which explained
in detail what was expected of them and then signed a consent form (Appendix B).
Subjects were permitted to continue any medication that they were previously taking prior
to initiating the program including over the counter NSAIDS and analgesics, and were
asked to engage in no form of physical therapy or prescribed exercise. Once the patients
agreed to participate in the study, the WOMAC was introduced and completed as a pre
test measure before receiving the first injection of either Synvisc or Hyalgan.
Forty one patients (20 Hyalgan, 21 Synvisc) received either Hyalgan or Synvisc
throughout the research protocol and were not permitted to switch or combine products.
The products were administered identically by the participating physicians. Since the
incidence o f adverse events related to the injection site are significantly influenced by the
mjection technique, we chose a lateral entry with a straight knee (Lussier, Cividino,
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McFarlane, Olszvnski, Potashner, & De Medicis, 1996) using a 20 gauge needle. Hyalgan
patients received one injection per week for five weeks and Synvisc patients received one
injection per week for three weeks. Two months following the completion o f injections,
each subject received, by mail, a WOMAC questionaire that served as the mid-test
measure. Participants received the final WOMAC, four months after the final injection
which served as the post-test measure. With the exception of the time required to
complete the WOMAC, subjects did not incur any additional expenses due to their
participation in this study as they were going to receive viscosupplementation treatment
regardless of their participation in the study.
Upon completion o f the three WOMAC questionaires, the researchers used a ruler to
determine the distance in millimeters from the left end marker of each line to the point at
which the patients mark intersected the line on the analogue scale. For each section (pain,
stiffness, daily activity) a sub-scale score was calculated by the summation o f each
measurement. For example, the total range for scores for pain was 0-500, for stiffness 0200. and for daily function 0-1700.

Data Analysis
Mean scores were analyzed using a 2 (Treatment) x 3(Time) factorial analysis of
variance (ANOVA) with repeated measures on the second factor (Time). Separate
ANOVA’s were used for each dependent variable: pain, stiffiiess, and daily function to
determine if there was a significant difference in functional efficacy between Hyalgan and
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Synvisc at pre-injection, two month post-injection, and four month post-injection and to
also determine overall product efficacy (please see Appendix D for raw data).
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CHAPTER 4

RESULTS

Pain
Research participants responded to five questions from each WOMAC questionaire ( 15
total: pre-test, two month test, and four month test) regarding the intensity of their knee
joint pain during various levels of activity. With each questionaire, there was a total
possible score for pain ranging from 0 to 500 for both Synvisc and Hyalgan. A significant
pre-test difference was found between Hyalgan and Synvisc participants prior to the first
injection for either group. Synvisc patients described a significantly higher initial pain
intensity (M=311.57) than Hyalgan patients (M=229.20) (p<0.05) possibly due to a
number of high outlier scores or low outlier scores (see Appendix E for scatterplot
scores). However, the two month WOMAC results revealed no significant difference
regarding pain between Synvisc patients (M=197.95) and Hyalgan patients (M=l 77.20)
(p>0.05). Similarly, the four month WOMAC results also yielded no significant
differences between Synvisc (M=l 17.95) and Hyalgan (M=97.15) (p>0.05).
Furthermore, there was a significant interaction between pain scores and time (pc.Ol)
possibly due to the fact that there was a significant difference between the pain scores of
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the Hyalgan and Synvisc groups on the initial WOMAC testing prior to the
commencement of the viscosupplementation protocol.

Pain
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Figure 1. Effects of Viscosupplementation on pain over time.

Stiffness
The WOMAC consists o f two questions pertaining to knee joint stiffness. The
participants answered the two identical questions on each WOMAC administration,
equaling six stiffness questions in all. The total possible score for stiffness on each
questionaire could range from 0 to 200 for both Hyalgan and Synvisc participants. Again,
the pre-test results revealed that there was a significant difference between Synvisc
patients and Hyalgan patients concerning perceived degree of stiffiiess prior to any
injection o f either product. Synvisc patients complained of significantly worse stiffiiess
(M=134.00) than did Hyalgan patients (M=102.30) (p<0.05) again, possibly due to a
number o f initial outlier scores for Synvisc (see Appendix E for scatterplot scores).
Similar to the pain results, by the two month questionnaire Hyalgan patients conveyed no

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

45
significant differences concerning stiffness (M=72.60) compared to Synvisc patients
(M=90.86) (p>0.05). Again, the same was true for the four month WOMAC, as the
differences between Synvisc (M=58.19) and Hyalgan (M=43.20) were not significant
(p>0.05).
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Figure 2. Effects o f viscosupplementation on stiffness over time.

Daily Activities
Questions regarding daily activity (functioning) comprise the major construct o f the
WOMAC questionnaire. There were 17 questions to answer for each WOMAC
administration in regard to daily functioning, with individual scores ranging from 0 to
1700 for each patient (see Appendix E for scatterplot scores). The results suggest that
there are no significant differences for daily functioning between Synvisc patients (pre-test
M=1066.5; two month test M=640.6; four month test M=361.95) and Hyalgan patients
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(pre-test M=890.4; two month test M=597.3; four month test M=340.45) within each of
the three WOMAC administrations.
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Figure 3. Effects of viscosupplementation on daily activities over time.

Overall Effectiveness
Although the purpose of this research was to compare and not question the
effectiveness o f Hyalgan and Symisc in their improvement of OA symptoms, this study, as
well as several preceding publications, resulted in finding that both products are highly
effective in decreasing pain and stiffîiess and increasing daily functioning. For Hyalgan the
results concluded that there was a significant difference in the decrease of pain from pre
test through the four month test (p<.000l). There was also a significant decrease in
stiffiiess (p<.0001) and a significant increase in daily functioning (p<.0001). The same
was also true for Synvisc resulting in a significant decrease in pain fi-om pre-test through
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the four month test (p<.0001). a significant decrease in stiffness (p<.0001), and a
significant increase in daily functioning (p<.0001) among the participants.
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CHAPTERS

DISCUSSION
The efficacy of viscosupplementation products for OA o f the knee have been
researched extensively especially in comparison to other forms of treatment for
osteoarthritis. Published results for these products support that they are highly effective in
decreasing pain and stiffness and increasing daily functioning for patients with OA.
Equally as important, studies have proven that viscosupplementation also yields by far the
smallest incidence of adverse effects when compared with other means of OA treatment
such as NSAIDS. analgesics, glucosamine, saline lavage, steroids, physical therapy, and
knee replacement (Creamer & Hochberg, 1997; Dieppe el al.. 1993; Harris, 1993; Wen.
2000; Goorman et al., 2000; Wright et al.,2000; Uebelhart & Williams, 1999). As a result
o f these findings, viscosupplementation is becoming an increasingly popular and preferred
treatment every year. Currently, the two FDA approved viscosupplementation products,
Hyalgan and Synvisc, are supported by vast publications concerning their effectiveness in
treating OA symptoms against the other types o f treatments.
The relationship between the molecular weight and viscosity o f each the treatment
products and functional efficacy has been a top priority o f the research to determine
whether or not viscosity is a key reason for the positive effectiveness. Most published
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studies such as one completed in 1994 by Aviad and Houpt, suggest that there are no
significant differences in product efficacy when comparing molecular weighL However, a
more recent study by Wobig et al. (1999) comparing Synvisc (6 millions dallons) to ARTZ
(similar to Hyalgan at 0.75 million daltons) concluded that Synvisc was significantly more
effective than ARTZ in decreasing pain and stiffiiess and increasing function. The authors
credited these findings to the much higher molecular weight of Synvisc, explaining that a
higher molecular weight product is more beneficial than a lower molecular weight
product. The importance of this study to our research revolves around the similarities
between Hyalgan and ARTZ in both composition and molecular weight. Physician and/or
patient knowledge of these similarities could infer that if Synvisc is more efficacious than
ARTZ then the same must be true for Hyalgan. The results from this study suggest that
there are no significant differences between Hyalgan and Synvisc when comparing
treatment efficacies, protocol, incidence o f adverse reactions, or cost to patient.
The study performed by Wobig et al., (1999) utilized 70 participants total based on a
comparison o f treatment groups using a two-tailed t test with an alpha factor of 0.05 and a
power of 0.8, meaning the minimum required sample size was 29 participants for each
group, a grand total of 58 patients. Our research utilized 20 Hyalgan and 21 Synvisc
patients, 41 participants total. Both the Hyalgan versus Synvisc study and the Synvisc
versus ARTZ study required very similar inclusion criteria for participants, used a marginal
number o f participants, used a multi-center aRiroach, relied on the WOMAC guide for
data and used similar statistical analysis to produce the results. The key difference
between the Synvisc/ARTZ and the Synvisc/Hyalgan studies was the injection protocol.
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Our study specifically followed the injection protocols recommended by each company.
Synvisc, due to its higher molecular weight, is to be administered in a course o f 3
injections while the lower molecular weight Hyalgan requires five injections. Wobig et al.
administered three injections of ARTZ which resulted in approximately 1 million 5
hundred thousand daltons less than what the recommended protocol o f five injections
pro\ides. Therefore when comparing overall treatment protocols, the ARTZ participants
were not receiving as much overall fluid viscosity (i.e. treatment) as the Synvisc
participants. As our study followed the suggested three Synvisc or five Hyalgan injection
protocols, the overall molecular weight o f the viscosupplement injections was relatively
similar across the two viscosupplements and may have eliminated any significant
differences between the two products. .\s such, it may be the overall amount or weight of
the viscosupplement that is injected throughout the course of the protocol that is crucial in
overall functional efficacy rather than the importance o f the molecular weight of each
individual viscosupplement.
Other studies focusing on the molecular weight o f viscosupplementation products are
concerned with a possible increase in the incidence of adverse effects due to higher
molecular weight compounds. Several researchers such as Puttnick e t al (1995) claim to
have found more adverse reactions such as increased injection site pain and swelling in
products with a higher molecular weight than with lower or very little molecular weighted
substances. Other studies indicate an increased participant drop out rate associated with
extreme injection site pain after the use o f a high molecular weight substance. There are
also reports o f injection site problems with lower molecular weight substances but not as
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extreme or as extensive. However, all o f these studies compared the
viscosupplementation product with saline injections, a placebo effect, or no injection at all.
The study by Wobig et al. (1999) that compared two viscosupplementation products, did
not mention any major problems with the injection site. The results o f our study
suggested no differences between the higher molecular weight treatment and the lower
molecular weight treatment regarding any type of injection site problem. However, the
WOMAC guide is not equipped with questions to indicate if the patient is having any
trouble with the injection site and these types of problems are generally either verbally
reported to the treating physician or by the participant halting further
viscosupplementation treatment.
Our study suggests that Hyalgan and Synvisc are both effective in their ultimate ability
to decrease pain and stiffness and increase daily functioning. The purpose of this study,
however, was not to determine the overall efficacy o f either Hyalgan or Synvisc in the
treatment of OA of the knee, but to compare the two. As previously mentioned, the
findings of this research did suggest that both viscosupplementation products produced a
significant decrease in pain and stiffness, and an increase in the daily function for patients
plagued with OA o f the knee. However, there was a significant difference between the
products at the pre-test level. Before any type o f treatment was administered, either
Synvisc patients recorded a significantly higher incidence o f pain and stiffness or the
reverse, Hyalgan patients recorded a significantly lower incidence of pain and stiffiiess. It
is important to mention again that these groups were randomly selected for each treatment
group and that these significant differences were recorded prior to any form of treatment.
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This was the pre-test WOMAC questionnaire. Reasons for this significant difference
between Hyalgan and Synvisc subjects at pre-test are unclear and could be explained by
many different scenarios. Coincidence could be one explanation in that there could have
been a few outliers whether high or low that just happened to be experiencing more or less
pain and stiffness than the rest o f the subjects. Perhaps weather played a role in the high
outlier perspective whereas a few subjects located in the same area experienced more pain
and stiffness due to colder weather conditions at the time of the pre-test. Some subjects
may have been confused while filling out the WOMAC for the first time during pre-test.
Perhaps directions for completion of the WOMAC differed fi’om patient to patient and
seemed unclear by some. Gender may have played a role or possibly just individual pain
tolerance. In any event, and there could be many more possibilities, the important issue is
the ultimate effectiveness for these patients once they did begin treatment. Once the two
month (mid-test) WOMAC was completed, there was no significant difference between
Hyalgan and Synvisc for their efficacy in decreasing pain and stiffness and increasing daily
functioning. The same was true upon completion of the four month (post-test) WOMAC,.
Hyalgan and Synvisc were not significantly different with patient improvement o f OA
symptoms. Because o f these findings that Hyalgan and Synvisc are comparably effective
in the treatment o f OA o f the knee, the results will aid in decision making for physicians
and patients between Hyalgan and Synvisc depending on individual preferences concerning
product, injection protocol, product availability and possibilities of adverse reactions.
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Directions for Future Research
Future study is needed to compare all types of viscosupplementation products
approved for use. Research o f such nature needs to be conducted to determine and
confirm the proper treatment protocol suggested by each product company. The
differences in fluid content regarding the amount o f HA or molecular weight require
specific injection guidelines for each product. Due to the mention in several published
studies of localized and more serious adverse reactions, a larger participant group,
possibly N=100, for each approved viscosupplementation product would be highly
recommended. In addition, due to findings of this study, it may be beneficial to analyze
pre-test results before administering treatment to assure that study group recordings are
accurate. The cost of treatment deters some patients from either participating in a
viscosupplementation program or unwilling to expend the extra effort that would be
required as a study participant. Therefore, compensation for the cost of the treatment for
anyone willing to participate is highly advisable and would open the door to the use of
additional measuring tools and could increase the sample size for each treatment group.
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W O M A C VA30 QUESTIONNAIRE
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WOMAC OSTEOARTHRITIS INDEX VERSION VA3.0
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WOMa

WOMAC VA3.0 QUESTIONNAIRE

Sw Hqa A
PAIN

Think «bout ih« pain you f«H In youf
due to your arthritis during the last 48 hours.
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WOMi

WOMAC VA30 QUESTIONNAIRE

ttc M n l
STIKNLSS

Think about Ih# slifA w (not pain) you
du# to your arthritis during the la^t 48 hours.

Stiffness is a sensation of decaeaed ease in moving your joint.
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WOMAC VA3 0 QUESTIONNAIRE

n i F r i C U l TY P F R r O R M I N G DAI LY A C T l V I T I t S
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WOMcai

WOMAC VA3 0 QUESTIONNAIRE
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